HLS Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	55.85	56.62	63.07	61.47	60.01	56.11
Revenue Growth (YoY)	-1.92%	-10.23%	2.61%	2.43%	6.95%	3.60%
Cost of Revenue	15.74	14.66	13.2	10.71	9.65	9.09
Gross Profit	40.11	41.96	49.88	50.76	50.36	47.02
Selling, General & Admin	20.64	25.31	28.82	26.93	24.02	23.39
Operating Expenses	44.75	49.65	60.23	64.26	56.64	59.1
Operating Income	-4.64	-7.69	-10.35	-13.5	-6.28	-12.09
Interest Expense	-8.5	-10.08	-8.75	-7.32	-6.96	-6.31
Interest & Investment Income	0.13	0.32	0.35	0.06	0.04	0.32
Currency Exchange Gain (Loss)	0.39	-0	0.05	-0.11	-0.41	-0.27
Other Non Operating Income (Expenses)	-1.21	-0.99	-1.73	1.54	1.8	2.75
EBT Excluding Unusual Items	-13.83	-18.44	-20.43	-19.33	-11.81	-15.59
Merger & Restructuring Charges	-	-	-	-	-	-0.71
Gain (Loss) on Sale of Assets	-	3.38	-	-	-	-
Asset Writedown	-	-	-3.89	-3.05	-	-
Other Unusual Items	-0.52	-0.52	-3.48	-1.34	-	-
Pretax Income	-13.83	-15.58	-27.8	-23.72	-11.81	-16.3
Income Tax Expense	0.29	4.07	-0.27	-0.12	1.31	-0.97
Net Income	-14.12	-19.66	-27.53	-23.6	-13.12	-15.33
Net Income to Common	-14.12	-19.66	-27.53	-23.6	-13.12	-15.33
Shares Outstanding (Basic)	32	32	32	32	32	32
Shares Outstanding (Diluted)	32	32	32	32	32	32
Shares Change (YoY)	-0.81%	-1.31%	-0.52%	0.77%	1.48%	8.01%
EPS (Basic)	-0.45	-0.62	-0.85	-0.73	-0.41	-0.48
EPS (Diluted)	-0.45	-0.62	-0.85	-0.73	-0.41	-0.48
Free Cash Flow	13.64	7.99	15.75	16.9	16.38	9.31
Free Cash Flow Per Share	0.43	0.25	0.49	0.52	0.51	0.29
Dividend Per Share	-	-	0.076	0.148	0.158	0.157
Dividend Growth	-	-	-48.76%	-6.50%	0.69%	1.79%
Gross Margin	71.82%	74.11%	79.07%	82.58%	83.92%	83.80%
Operating Margin	-8.31%	-13.58%	-16.41%	-21.96%	-10.47%	-21.54%
Profit Margin	-25.28%	-34.71%	-43.65%	-38.39%	-21.86%	-27.32%
Free Cash Flow Margin	24.43%	14.11%	24.97%	27.49%	27.30%	16.59%
EBITDA	17.1	14.99	21.52	20.8	23.4	20.62
EBITDA Margin	30.62%	26.47%	34.13%	33.83%	39.00%	36.75%
D&A For EBITDA	21.74	22.67	31.87	34.29	29.69	32.71
EBIT	-4.64	-7.69	-10.35	-13.5	-6.28	-12.09
EBIT Margin	-8.31%	-13.58%	-16.41%	-21.96%	-10.47%	-21.54%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.